Literature DB >> 9266573

Off-label prescribing during pregnancy.

W F Rayburn1, K C Farmer.   

Abstract

Obstetricians frequently prescribe drugs for indications other than those on the product label. Reasons for such off-label use during pregnancy include prevention of repetitive abortion, inhibition of premature labor, reduction of fetal or neonatal infection, reduction in development of preeclampsia and its complications, and ripening of the cervix or induction of labor. A physician has a legal right to prescribe for off-label indications despite regulatory, manufacturer, and cost constraints. Such prescribing habits would not be considered experimental if based on sound scientific evidence. Adequate and well-controlled studies are difficult, however, to perform during pregnancy. Evidence of widespread use and support from another qualified clinician are methods of justifying off-label prescribing. Each patient is entitled to know why she and her fetus would benefit from the treatment and whether any unnecessary risk is anticipated. Legible documentation of these discussions in the medical records is important.

Entities:  

Mesh:

Year:  1997        PMID: 9266573     DOI: 10.1016/s0889-8545(05)70317-x

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  8 in total

Review 1.  A benefit-risk assessment of misoprostol for cervical ripening and labour induction.

Authors:  Deborah A Wing
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Off-label prescribing: a call for heightened professional and government oversight.

Authors:  Rebecca Dresser; Joel Frader
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

3.  Clinical therapeutics in pregnancy.

Authors:  Maisa N Feghali; Donald R Mattison
Journal:  J Biomed Biotechnol       Date:  2011-07-06

4.  Off-label use of ondansetron in pregnancy in Western Australia.

Authors:  Lyn Colvin; Andrew W Gill; Linda Slack-Smith; Fiona J Stanley; Carol Bower
Journal:  Biomed Res Int       Date:  2013-12-12       Impact factor: 3.411

5.  Successful treatment of ptyalism gravidarum with clonidine hydrochloride: A case report.

Authors:  Victoria De Braga; Elias M Dahdouh; Jacques Balayla
Journal:  Case Rep Womens Health       Date:  2022-04-06

Review 6.  Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.

Authors:  Dylan van de Vusse; Paola Mian; Sam Schoenmakers; Robert B Flint; Willy Visser; Karel Allegaert; Jorie Versmissen
Journal:  Eur J Clin Pharmacol       Date:  2022-09-15       Impact factor: 3.064

Review 7.  A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors.

Authors:  Vincenzo Raimondi; Nicolas Thomas Iannozzi; Jessica Burroughs-Garcìa; Denise Toscani; Paola Storti; Nicola Giuliani
Journal:  Explor Target Antitumor Ther       Date:  2022-08-31

Review 8.  Regulating off-label drug use in India: The arena for concern.

Authors:  Sukhvinder Singh Oberoi
Journal:  Perspect Clin Res       Date:  2015 Jul-Sep
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.